What is the standard dosing protocol for CJC-1295 with DAC?

Conventional CJC-1295 with DAC dosing is 1-2 mg 1-2x weekly via subq. For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the mechanism of action of CJC-1295 with DAC?

Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. For anabolic and recovery applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The body composition / training interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What should I look for in CJC-1295 with DAC sourcing and quality?

Acceptable CJC-1295 with DAC certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~3367 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What are the safety considerations for CJC-1295 with DAC?

Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible. For anabolic and recovery use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. CJC-1295 with DAC's ~6-8 days (with DAC) pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Will CJC-1295 with DAC actually increase lean mass?

CJC-1295 with DAC's effect on body composition depends on which dimension of the anabolic cascade it engages. Direct GH/IGF-axis engagement supports lean mass through protein synthesis and satellite cell activation. Effect size is proportional to training stimulus and nutritional adequacy.

Home/ Compounds/ CJC-1295 with DAC

CJC-1295 with DAC

Body Composition

Athletes and performance coaches evaluating CJC-1295 with DAC for body composition focus on three measurable endpoints: lean mass, recovery capacity, and the rate of return to training intensity between sessions. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1.. The 1-2 mg 1-2x weekly protocol over the standard 8-12 week cycle, paired with training stimulus and nutritional adequacy, is where the body-composition response is generated.

Body Composition / Training Applications

HyperplasiaBody RecompositionRecoveryTraining PerformanceCardiovascular Conditioning

Key Takeaways

Body composition lens: response to CJC-1295 with DAC is proportional to training stimulus and nutritional adequacy.
Mechanism: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release.
Body composition dose: 1-2 mg 1-2x weekly via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

For trained users, CJC-1295 with DAC's body composition response is generated at the intersection of compound pharmacology, training stimulus, and nutritional input. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. The mechanism informs which training and nutrition pattern maximises the response; the subsections below work through this for the four dimensions tracked in body composition protocols.

Recovery window and training frequency

The most reliably reported effect of CJC-1295 with DAC in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. CJC-1295 with DAC with a ~6-8 days (with DAC) half-life of ~6-8 days (with DAC) is long-lived enough that daily dosing matters less than total exposure per cycle. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where CJC-1295 with DAC demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Body Composition / Training Applications

Recovery

For recovery, CJC-1295 with DAC integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Strength

Strength responds to CJC-1295 with DAC with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Lean Mass

The body composition community converges on CJC-1295 with DAC for lean mass with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Cardiovascular Conditioning

For cardiovascular conditioning, CJC-1295 with DAC integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Body Composition focus	SubQ	1-2 mg	1-2x weekly
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for CJC-1295 with DAC is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 with DAC stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

CJC-1295 with DAC + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with CJC-1295 with DAC's mechanism in body composition / training protocols.
CJC-1295 with DAC + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with CJC-1295 with DAC's mechanism in body composition / training protocols.
CJC-1295 with DAC + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with CJC-1295 with DAC's mechanism in body composition / training protocols.
CJC-1295 with DAC + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with CJC-1295 with DAC's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Banned (S2 class) FDA: Unapproved Research: Phase II human data; widely used off-label

Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible.

Lens-specific safety considerations for body composition / training use of CJC-1295 with DAC: Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

CJC-1295 sustained release of growth hormone in healthy adults

PMID 16940290

Supporting

Long-acting GHRH analogue mechanism and pharmacokinetics

PMID 16352683

CJC-1295 with DAC vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 with DAC	Long-acting GHRH analogue	~6-8 days (with DAC)	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

Can I use CJC-1295 with DAC alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

Best stack pairing for lean mass?

The canonical lean mass stack pairs CJC-1295 with DAC with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Should I cycle CJC-1295 with DAC?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

What does CJC-1295 with DAC stack well with?

For body composition / training protocols, CJC-1295 with DAC pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from CJC-1295 with DAC's primary mechanism (Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release), producing additive or synergistic effects rather than receptor competition.

What is the evidence base for CJC-1295 with DAC?

CJC-1295 with DAC's evidence base sits at phase ii human data; widely used off-label. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Clinical Protocol

Start a CJC-1295 with DAC Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified CJC-1295 with DAC and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: ~3367 Da
Sequence length: 30 aa
Half-life: ~6-8 days (with DAC)
WADA: Banned (S2 class)
FDA: Unapproved
Research: Phase II human data; widely used off-label

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 with DAC unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for CJC-1295 with DAC

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised